Wilding, John http://orcid.org/0000-0003-2839-8404
Article History
First Online: 22 October 2019
Competing interests
: JW has undertaken consultancy work and given lectures on behalf of Astellas, AstraZeneca, Boehringer Ingelheim, Janssen, Merck Sharpe and Dohme, all of whom produce SGLT2 inhibitors. JW has been an investigator for several SGLT2 inhibitor trials and was a member of the DECLARE TIMI-58 trial steering committee. JW has also undertaken consultancy, undertaken clinical trials and given lectures on behalf of companies that produce other treatments for diabetes mellitus, namely Novo Nordisk, Eli Lilly, Sanofi and Takeda. JW received renumeration for time spent as a consultant and time spent on clinical trials via his employing institution, the University of Liverpool.